ReviewTherapeutic advances in drug safety2015
Abuse-deterrent formulations: transitioning the pharmaceutical market to improve public health and safety.
Review in Therapeutic advances in drug safety, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Abuse-deterrent wearable device with potential for extended delivery of opioid drugs.Biomedical engineering letters · 2025Article
- Postmarketing Research for Opioid Abuse-Deterrent Formulations: A Narrative Review.Journal of pain research · 2025Review
- Advancement in Opioid Abuse-deterrent Formulation Technologies and Regulatory Expectation.Current drug research reviews · 2025Review
- People who inject oral morphine favor experimentation with injectable opioid substitution.Harm reduction journal · 2023Article
- Future Treatment of Neuropathic Pain in Spinal Cord Injury: The Challenges of Nanomedicine, Supplements or Opportunities?Biomedicines · 2022Article
- Non-medical Use of Prescription Stimulants Among College Students: Non-oral Routes of Administration, Risk Factors, Motivations, and Pathways.Frontiers in psychiatry · 2021Article
- Risk assessment of using off-label morphine sulfate in a population-based retrospective cohort of opioid-dependent patients.British journal of clinical pharmacology · 2020Article
- The opioid crisis in North America: facts and future lessons for Europe.Anaesthesiology intensive therapy · 2020Review
- Dancing with Deterrents: Understanding the Role of Abuse-Deterrent Opioid Formulations and Naloxone in Managing Cancer Pain.The oncologist · 2019Article
- Redeveloping Substance Abuse Treatment for Military Personnel.Current psychiatry reports · 2018Review
- Abuse-deterrent formulations: transitioning the pharmaceutical market to improve public health and safety.Therapeutic advances in drug safety · 2015Article
- Abuse-deterrent formulations: transitioning the pharmaceutical market to improve public health and safety-reply.Therapeutic advances in drug safety · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article evaluates abuse-deterrent formulations (ADFs) as a method to reduce prescription drug abuse while ensuring access to vital medications for individuals with legitimate need; assesses the pros and cons of ADFs and the current state of ADF adoption in the market; and develops policy recommendations to transition the market to ADFs. Although abuse-deterrent technology is still in its nascent stages, ADFs have been proven to reduce prescription drug abuse and its consequences, and even an incremental reduction in abuse can have a significant impact on the nation by reducing the costly social, physical, mental, and public health problems resulting from abuse. Federal ADF policy does not reflect the urgency of the prescription drug abuse epidemic and does not go far enough toward changing the status quo. Policies must be implemented to encourage innovation and a market shift toward ADFs by ensuring any generic medication that references a branded ADF demonstrates that it does not have abuse-deterrent properties inferior to the branded ADF product. Policies must also require federal prescription drug benefit plans to cover ADFs to ensure consumers have access to such medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.